Type your tag names separated by a space and hit enter

Metformin in cancer prevention and therapy.

Abstract

The prevalence of diabetes is dramatically increasing worldwide. The results of numerous epidemiological studies indicate that diabetic population is not only at increased risk of cardiovascular complications, but also at substantially higher risk of many forms of malignancies. The use of metformin, the most commonly prescribed drug for type 2 diabetes, was repeatedly associated with the decreased risk of the occurrence of various types of cancers, especially of pancreas and colon and hepatocellular carcinoma. This observation was also confirmed by the results of numerous meta-analyses. There are however, several unanswered questions regarding the exact mechanism of the anticancer effect of metformin as well as its activity against various types of cancer both in diabetic and nondiabetic populations. In the present work we discuss the proposed mechanism(s) of anticancer effect of metformin and preclinical and clinical data suggesting its anticancer effect in different populations.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Internal Diseases, Diabetology and Clinical Pharmacology, Medical University of Lodz, ul. Pomorska 251, 92-213 Lodz, Poland.

    ,

    Department of Internal Diseases, Diabetology and Clinical Pharmacology, Medical University of Lodz, ul. Pomorska 251, 92-213 Lodz, Poland.

    Department of Internal Diseases, Diabetology and Clinical Pharmacology, Medical University of Lodz, ul. Pomorska 251, 92-213 Lodz, Poland.

    Source

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    25333032

    Citation

    Kasznicki, Jacek, et al. "Metformin in Cancer Prevention and Therapy." Annals of Translational Medicine, vol. 2, no. 6, 2014, p. 57.
    Kasznicki J, Sliwinska A, Drzewoski J. Metformin in cancer prevention and therapy. Ann Transl Med. 2014;2(6):57.
    Kasznicki, J., Sliwinska, A., & Drzewoski, J. (2014). Metformin in cancer prevention and therapy. Annals of Translational Medicine, 2(6), p. 57. doi:10.3978/j.issn.2305-5839.2014.06.01.
    Kasznicki J, Sliwinska A, Drzewoski J. Metformin in Cancer Prevention and Therapy. Ann Transl Med. 2014;2(6):57. PubMed PMID: 25333032.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Metformin in cancer prevention and therapy. AU - Kasznicki,Jacek, AU - Sliwinska,Agnieszka, AU - Drzewoski,Józef, PY - 2014/03/15/received PY - 2014/05/23/accepted PY - 2014/10/22/entrez PY - 2014/10/22/pubmed PY - 2014/10/22/medline KW - Metformin KW - cancer KW - clinical evidence KW - molecular action SP - 57 EP - 57 JF - Annals of translational medicine JO - Ann Transl Med VL - 2 IS - 6 N2 - The prevalence of diabetes is dramatically increasing worldwide. The results of numerous epidemiological studies indicate that diabetic population is not only at increased risk of cardiovascular complications, but also at substantially higher risk of many forms of malignancies. The use of metformin, the most commonly prescribed drug for type 2 diabetes, was repeatedly associated with the decreased risk of the occurrence of various types of cancers, especially of pancreas and colon and hepatocellular carcinoma. This observation was also confirmed by the results of numerous meta-analyses. There are however, several unanswered questions regarding the exact mechanism of the anticancer effect of metformin as well as its activity against various types of cancer both in diabetic and nondiabetic populations. In the present work we discuss the proposed mechanism(s) of anticancer effect of metformin and preclinical and clinical data suggesting its anticancer effect in different populations. SN - 2305-5839 UR - https://www.unboundmedicine.com/medline/citation/25333032/full_citation L2 - http://dx.doi.org/10.3978/j.issn.2305-5839.2014.06.01 DB - PRIME DP - Unbound Medicine ER -